Despite Production Guidance, Lucid Faces a Long Road Ahead
Lucid has set a production target, but many investors wonder if the pace will match the plan. This deep dive explains...
Identify the most severe drawdowns in index fund history and review their recovery paths to inform risk management.
16,017 articlesLucid has set a production target, but many investors wonder if the pace will match the plan. This deep dive explains...
Kick off your weekend with a thoughtful set of friday reads designed to inform, not echo headlines. This guide blends...
Netflix faces a crossroads: expand by merging with major studios or double down on core strengths. This piece argues ...
Virginia’s starting question whether its data-center incentives are delivering broad value has moved into a high-stak...
In Washington, governors from both parties pressed for a sweeping review of the nation’s workforce policy amid AI-dri...
BlackRock launches a new staked Ethereum trust on Nasdaq, combining price upside with validator yields. The move mark...
Thinking about investing in artificial intelligence stocks hold for the long run? This article breaks down two depend...
Novo Nordisk has faced headwinds, but a new GLP-1 drug could change the game. This article breaks down what investors...
Lucid Group faces a bumpy road as the EV market evolves. This report outlines 2026-2030 price paths for lucid group (...
Salesforce delivered a solid Q4 beat and announced a $50 billion buyback, but FY27 guidance disappointed investors. T...
A biotech stock that surged 135% in a year suddenly sees a big investor trim its stake by about $44 million. Here’s h...
MaxCyte's 2025 earnings journey hinges on platform momentum, partnerships, and cash discipline. This guide breaks dow...